Effectiveness of the Information Technology-Aided Program of Relapse Prevention in Schizophrenia (ITAREPS): A Randomized, Controlled, Double-Blind Study

被引:59
作者
Spaniel, Filip [1 ]
Hrdlicka, Jan [2 ]
Novak, Tomas [1 ]
Kozeny, Jiri [1 ]
Hoeschl, Cyril [1 ]
Mohr, Pavel [1 ]
Motlova, Lucie Bankovska [1 ]
机构
[1] Charles Univ Prague, Fac Med 3, Prague Psychiat Ctr, Ctr Neuropsychiat Studies, Prague 18103 8, Czech Republic
[2] Czech Tech Univ, Fac Elect Engn, Dept Cybernet, CR-16635 Prague, Czech Republic
关键词
schizophrenia; psychotic disorders; relapse prevention; hospitalizations; antipsychotic medication; information technology; FOLLOW-UP; THERAPY; PREDICTION; SYMPTOMS; EPISODE; COSTS; SIGNS;
D O I
10.1097/01.pra.0000416017.45591.c1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose. To evaluate the effectiveness of the Information Technology-Aided Program of Re lapse Prevention in Schizophrenia (ITAREPS). Methods. Relapse-prone outpatients with schizophrenia or schizoaffective disorder were randomized to the active (n = 75) or control group (n = 71). In the active arm, according to the protocol, investigators were prompted to increase the antipsychotic dose upon occurrence of a pharmacological intervention requiring event (PIRE) detected by ITAREPS. Results. Intention-to-treat (ITT) analysis found no between-group difference in the hospitalization-free survival rate at 12 months. However, the trial suffered from high non-adherence of investigators in the active group, with no antipsychotic dose increase in 61% of PIREs. Furthermore, Cox regression analysis showed a 11-fold increased risk of hospitalization in the absence of pharmacological intervention following a PIRE (hazard ratio [HR] = 10.8; 95% confidence interval [CI] 1.4-80.0; p = 0.002). Therefore, a post-hoc as-treated analysis was performed, which demonstrated a nine-fold reduction in the risk of hospitalization in ITAREPS Algorithm-Adherers (IAAs, n = 25) compared with the ITAREPS Non-interventional group (INIs, n = 70; Kaplan-Meier survival analysis, HR = 0.11, 95% CI 0.05-0.28, p = 0.009; number needed to treat [NNT] = 4, 95% CI 3-10). A significant difference in favor of the IAA group was seen in the number of inpatient days (p < 0.05) and costs (p < 0.05). Conclusion. Future ITAREPS trials should target the underlying mechanisms that cause low investigator adherence to the program. Trial registration: Clinical Trials NCT00712660 (Journal of Psychiatric Practice 2012; 18: 269-280)
引用
收藏
页码:269 / 280
页数:12
相关论文
共 30 条
  • [21] Spending for mental health and substance abuse treatment, 1996
    McKusick, D
    Mark, TL
    King, E
    Harwood, R
    Buck, JA
    Dilonardo, J
    Genuardi, JS
    [J]. HEALTH AFFAIRS, 1998, 17 (05) : 147 - 157
  • [22] THE NATURAL-HISTORY OF SCHIZOPHRENIA - A 5-YEAR FOLLOW-UP-STUDY OF OUTCOME AND PREDICTION IN A REPRESENTATIVE SAMPLE OF SCHIZOPHRENICS
    SHEPHERD, M
    WATT, D
    FALLOON, I
    SMEETON, N
    [J]. PSYCHOLOGICAL MEDICINE, 1989, : 1 - +
  • [23] The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up
    Spaniel, F.
    Vohlidka, P.
    Kozeny, J.
    Novak, T.
    Hrdlicka, J.
    Motlova, L.
    Cermak, J.
    Hoeschl, C.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (12) : 1943 - 1946
  • [24] ITAREPS:: Information technology aided relapse prevention programme in schizophrenia
    Spaniel, Filip
    Vohlidka, Pavel
    Hrdlicka, Jan
    Kozeny, Jiri
    Novak, Tomas
    Motlova, Lucie
    Cermak, Jan
    Bednarik, Josef
    Novak, Daniel
    Hoschl, Cyril
    [J]. SCHIZOPHRENIA RESEARCH, 2008, 98 (1-3) : 312 - 317
  • [25] PRODROMAL SIGNS AND SYMPTOMS OF SCHIZOPHRENIC RELAPSE
    SUBOTNIK, KL
    NUECHTERLEIN, KH
    [J]. JOURNAL OF ABNORMAL PSYCHOLOGY, 1988, 97 (04) : 405 - 412
  • [26] An economic review of compliance with medication therapy in the treatment of schizophrenia
    Thieda, P
    Beard, S
    Richter, A
    Kane, J
    [J]. PSYCHIATRIC SERVICES, 2003, 54 (04) : 508 - 516
  • [27] Focal gray matter changes in schizophrenia across the course of the illness: A 5-year follow-up study
    van Haren, Neeltje E. M.
    Pol, Hilleke E. Hulshoff
    Schnack, Hugo G.
    Cahn, Wiepke
    Mandl, Rene C. W.
    Collins, D. Louis
    Evans, Alan C.
    Kahn, Rene S.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2007, 32 (10) : 2057 - 2066
  • [28] COST OF RELAPSE IN SCHIZOPHRENIA
    WEIDEN, PJ
    OLFSON, M
    [J]. SCHIZOPHRENIA BULLETIN, 1995, 21 (03) : 419 - 429
  • [29] Natural course of Schizophrenic disorders: A 15-year followup of a Dutch incidence cohort
    Wiersma, D
    Nienhuis, FJ
    Slooff, CJ
    Giel, R
    [J]. SCHIZOPHRENIA BULLETIN, 1998, 24 (01) : 75 - 85
  • [30] World Health Organization, 1992, International Statistical Classification of Diseases and related health problems